Anupam Rasayan re-appoints internal, cost auditors for FY27

1 min read Updated on 25 May 2026, 08:00 PM

Reviewed by

Riya DScanX News Team

AI Summary

Anupam Rasayan India Limited has re-appointed M/s. K.B. Daliya & Associates as its Internal Auditor and M/s. Bhanwarlal Gurjar & Co. as its Cost Auditor for the financial year 2026-27. The Board approved these appointments on May 23, 2026, following Audit Committee recommendations.

*this image is generated using AI for illustrative purposes only.

Anupam Rasayan India Limited has approved the re-appointment of its internal and cost auditors for the upcoming financial year. The decisions were made during a Board meeting held on May 23, 2026, based on the recommendations of the Audit Committee.

The Board re-appointed M/s. K.B. Daliya & Associates, Chartered Accountants, Surat, as the Internal Auditor to conduct the internal audit for the financial year 2026-27. The firm, with registration number 126368W, is a proprietorship firm established in 2005 by CA Ketan Daliya. It possesses extensive experience in internal audit, statutory audit, tax audit, and management consultancy.

Furthermore, the company re-appointed M/s. Bhanwarlal Gurjar & Co., Cost Accountants, Surat, as the Cost Auditor to audit the cost records maintained by the company for the financial year 2026-27. This firm, registered under number 101540, is a proprietorship cost and management accounting firm managed by CMA Bhanwar Lal Gurjar. The firm specializes in cost audit, internal audit, and management information systems across various industries including pharmaceuticals and chemicals.

The meeting commenced at 12:45 p.m. IST and concluded at 04:55 p.m. IST. The disclosures regarding these appointments were made in accordance with Regulation 30 of the SEBI Listing Regulations and the relevant SEBI Master Circular.

Auditor Details

Auditor Firm	Type	Registration Number	Location	Tenure
M/s. K.B. Daliya & Associates	Internal Auditor	126368W	Surat	FY 2026-27
M/s. Bhanwarlal Gurjar & Co.	Cost Auditor	101540	Surat	FY 2026-27

Historical Stock Returns for Anupam Rasayan

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.37%	-0.36%	+2.07%	+9.97%	+43.24%	+78.46%

How might the continuity of these auditors influence Anupam Rasayan's compliance and risk management strategies in FY 2026-27?

What are the expected cost implications of retaining the same audit firms for the upcoming financial year?

Could the re-appointment of these auditors signal any upcoming strategic shifts or operational changes within the company?

Earnings Call Details

The company will review its standalone and consolidated performance for Q4 and FY26 during the session. Management will address the operational and financial outcomes of the specified period. Participants are required to pre-register for the event using the provided link to gain access.

Key Participants

The earnings call will feature senior leadership from the company, providing insights into the quarterly and annual performance. The roster of participants includes the Managing Director, Chief Executive Officer, and other financial heads.

Designation	Name
Managing Director	Mr. Anand Desai
Chief Executive Officer	Mr. Gopal Agrawal
Chief Financial Officer	Mr. Amit Khurana
Deputy Chief Financial Officer	Mr. Vishal Thakkar

Access Information

Interested participants can join the conference call using various access numbers provided for different regions. The company has listed specific primary and toll-free numbers for attendees in India, the USA, the UK, Singapore, and Hong Kong.

Category	Access Numbers
Primary Number	+91 22 6280 1488, +91 22 7115 8869
Toll Free (USA)	1 866 746 2133
Toll Free (UK)	0 808 101 1573
Toll Free (Singapore)	800 101 2045
Toll Free (Hong Kong)	800 964 448

Strategic Growth Advisors Pvt. Ltd. is managing the RSVP for the event. Stakeholders can contact Mr. Shrikant Sangani or Ms. Shaily Patwa for further inquiries regarding the registration process.

Historical Stock Returns for Anupam Rasayan

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.37%	-0.36%	+2.07%	+9.97%	+43.24%	+78.46%

How has Anupam Rasayan's revenue from long-term contracts with global agrochemical and pharmaceutical clients evolved in FY26, and what is the pipeline outlook for FY27?

Given the specialty chemicals sector's exposure to China-plus-one supply chain shifts, how is Anupam Rasayan positioned to capture incremental business from multinational companies diversifying away from Chinese suppliers?

What is the status of Anupam Rasayan's capacity expansion projects, and how will new facilities impact margins and order book growth in the near to medium term?